Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
By Matt Grossman
Humanigen Inc.'s ifabotuzumab drug achieved positive results in a Phase 1 safety and bio-imaging trial in patients with glioblatoma multiforme, the company said Friday.
Glioblatoma multiforme is a type of brain cancer.
At both doses in the study, ifabotuzumab showed sensitive and specific tumor targeting in all the patients who received it, Humanigen said. The adverse events in the study were readily manageable, the company said.
Andrew Scott, the study's principal investigator, said the results support further investigation of the drug's effect on other solid tumors in a Phase 2 study.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 09, 2021 07:27 ET (11:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results
DJ Humanigen的抗腫瘤Ifaotuzumab一期結果呈陽性
By Matt Grossman
馬特·格羅斯曼(Matt Grossman)著
Humanigen Inc.'s ifabotuzumab drug achieved positive results in a Phase 1 safety and bio-imaging trial in patients with glioblatoma multiforme, the company said Friday.
Humanigen公司週五表示，該公司的ifobtuzumab藥物在多形性膠質母細胞瘤患者的一期安全性和生物成像試驗中取得了積極的結果。
Glioblatoma multiforme is a type of brain cancer.
多形性膠質母細胞瘤是一種腦癌。
At both doses in the study, ifabotuzumab showed sensitive and specific tumor targeting in all the patients who received it, Humanigen said. The adverse events in the study were readily manageable, the company said.
Humanigen説，在研究中的兩種劑量下，ifobtuzumab在所有接受治療的患者中都顯示出敏感和特異的腫瘤靶向。該公司表示，研究中的不良事件很容易控制。
Andrew Scott, the study's principal investigator, said the results support further investigation of the drug's effect on other solid tumors in a Phase 2 study.
該研究的首席研究員安德魯·斯科特(Andrew Scott)説，這一結果支持在第二階段研究中進一步研究該藥物對其他實體腫瘤的影響。
Write to Matt Grossman at matt.grossman@wsj.com
寫信給馬特·格羅斯曼(Matt Grossman)，電子郵件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
April 09, 2021 07:27 ET (11:27 GMT)
2021年04月09日07：27(格林尼治標準時間11：27)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧